Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases  

作　　者：Zhiwei Chen Yuting Wang Taiyu He Hu Li Ling Ao Qingbo Pan Yingzhi Zhou Qian Zhu Dejuan Xiang Gaoli Zhang Ning Ling Min Chen Peng Hu Mingli Peng Dachuan Cai Dazhi Zhang Hong Ren 

机构地区：[1]Department of Infectious Diseases,the Second Affiliated Hospital of Chongqing Medical University,Chongqing,China [2]Key Laboratory of Molecular Biology for Infectious Diseases(Ministry of Education),Institute for Viral Hepatitis,the Second Affiliated Hospital of Chongqing Medical University,Chongqing,China

出　　处：《Journal of Clinical and Translational Hepatology》2024年第2期162-171,共10页临床与转化肝病杂志（英文版）

基　　金：supported by the National Science and Technology Major Project of China(Nos 2017ZX10202203-007,2017ZX10202203-008,2018ZX10302206-003)and a pilot project of clinical cooperation between traditional Chinese and western medicine for significant and complicated diseases of National Administration of Traditional Chinese Medicine:hepatic fibrosis.We also acknowledge the support of the National Natural Science Foundation of China(No 81772198);Natural Science Foundation of Chongqing,China(No.cstc2020jcyjmsxmX0389).

摘　　要：Background and Aims:SARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports.However,the safety and immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in patients with autoimmune liver diseases(AILD)is still unknown.Methods:Eighty-four patients with AILD were prospectively followed up after the second dose(primary)of inactivated SARS-CoV-2 vaccine.Some of them received the third dose(booster)of inactivated vaccine.Adverse events(AEs),autoimmune activation,and liver inflammation exacerbation after primary and booster vaccination were recorded.Meanwhile,dynamics of antireceptor-binding-domain IgG(anti-RBD-IgG),neutralizing antibodies(NAbs)and RBD-specific B cells responses were evaluated.Results:The overall AEs in AILD patients after primary and booster vaccination were 26.2%and 13.3%,respectively.The decrease of C3 level and increase of immunoglobulin light chain K andλlevels were observed in AILD patients after primary vaccination,however,liver inflammation was not exacerbated,even after booster vaccination.Both the seroprevalence and titers of anti-RBD-IgG and NAbs were decreased over time in AILD patients after primary vaccination.Notably,the antibody titers were significantly elevated after booster vaccination(10-fold in anti-RBD-IgG and 7.4-fold in NAbs,respectively),which was as high as in healthy controls.Unfortunately,the inferior antibody response was not enhanced after booster vaccination in patients with immunosuppressants.Changes of atypical memory B cells were inversely related to antibody levels,which indicate that the impaired immune memory was partially restored partly by the booster vaccination.Conclusions:The well tolerability and enhanced humoral immune response of inactivated vaccine supports an additional booster vaccination in AILD patients without immunosuppressants.

关 键 词：SARS-CoV-2 Autoimmune liver disease Inactivated SARS-CoV-2 vaccine SAFETY Antibody responses Memory B cells 

分 类 号：R575[医药卫生—消化系统]